APO-DEXLANSOPRAZOLE DIN 02529025
Health Canada record
| Active ingredient(s) | DEXLANSOPRAZOLE 60 MG |
|---|---|
| Dosage form | Capsule (Delayed-Release) |
| Route | Nasogastric; Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A02BC06 DEXLANSOPRAZOLE |
| Original market date | 26-Feb-2024 |
| Current status date | 26-Feb-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DEXLANSOPRAZOLE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02528991 | APO-DEXLANSOPRAZOLE | APOTEX INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 30 MG | Marketed |
| 02354969 | DEXILANT | TAKEDA CANADA INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 60 MG | Marketed |
| 02354950 | DEXILANT | TAKEDA CANADA INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 30 MG | Marketed |
| 02536404 | DEXLANSOPRAZOLE | ALTIUS HEALTHCARE INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 60 MG | Cancelled Post Market |
| 02523361 | DEXLANSOPRAZOLE | TAKEDA CANADA INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 60 MG | Cancelled Pre Market |
| 02523353 | DEXLANSOPRAZOLE | TAKEDA CANADA INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 30 MG | Cancelled Pre Market |
| 02536390 | DEXLANSOPRAZOLE | ALTIUS HEALTHCARE INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 30 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32598 | 2024-01-25 | Abbreviated New Drug Submission (ANDS) |
International API supply for DEXLANSOPRAZOLE
23 active FDA Drug Master Files.
Request a quote for APO-DEXLANSOPRAZOLE